secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0001104659-24-003908
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia reacquires MicroPine rights from B&L for $2M cash + $3M stock
----------------------------------------------------------------------

- Reacquired U.S. and Canada rights to MicroPine (late-phase III pediatric progressive myopia) from Bausch + Lomb Ireland.
- Consideration: $2M upfront cash + $3M in common stock + low single-digit royalty on net sales in U.S./Canada.
- MicroPine uses Optejet dispenser; market estimated at ~$2B annually in the U.S. by Review of Myopia Management.
- Ongoing CHAPERONE trial to be transferred; Eyenovia plans to meet with FDA to explore expedited development path.
- No impact on partnership with Arctic Vision covering Greater China and South Korea.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924003908/0001104659-24-003908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924003908/tm243285d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-003908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer